6 completed, 2 withdrawn, 1 enrolling by invitation, 1 not yet recruiting. 3 Phase 3, 2 Phase 1, 2 Phase 2, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 2, Withdrawn 1 |
| Phase 1 | 2 | Completed 1, Withdrawn 1 |
| Phase 2 | 2 | Completed 1, Not yet recruiting 1 |
| Not applicable | 1 | Completed 1 |
Follow Guillain-Barré Syndrome: new trials by email Literature Review of Guillain-Barré Syndrome trials Research Report on Guillain-Barré Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Efgartigimod in the Treatment of Guillain-Barré Syndrome(GREAT) Intravenous immunoglobulin (IVIG), Efgartigimod Alfa-Fcab - Guillain-Barré Syndrome | Phase 2 | Not yet recruiting | Beijing Tiantan Hospital | 110 | 2026-09-01 | 2026-09-18 |
| Development and Validation of the FBIndex to Determine the Risk of Falls for Patients With Neuromuscular Disorders FBIndex - Inclusion Body Myositis, Myotonic Dystrophy | Enrolling by invitation | LMU Klinikum | 108 | 2024-09-09 | 2025-09-10 | |
| RehabGBs: Rehabilitation in People With Guillain-Barré Syndrome Inpatient Rehabilitation, Inspiratory muscle training - Guillain-Barré Syndrome | Not applicable | Completed | Centro de Reabilitacao do Norte | 40 | 2023-01-01 | 2026-10-23 |
| A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Participants With Guillain-Barré Syndrome (GBS) Crovalimab, Placebo, Intravenous immunoglobulin therapy - Guillain-Barré Syndrome | Phase 3 | Withdrawn | Hoffmann-La Roche | 2022-11-30 | 2022-12-15 | |
| A Clinical Trial of CK0801 (a New Drug) In Patients With Treatment-Resistant Guillain-Barré Syndrome (GBS) CK0801 - Guillain-Barré Syndrome | Phase 1 | Withdrawn | Cellenkos, Inc. | 2022-11-01 | 2023-01-04 | |
| A Clinical Study of ANX005 and IVIG in Subjects With Guillain Barré Syndrome (GBS) ANX005, Intravenous immunoglobulin - Guillain-Barré Syndrome | Phase 1 | Completed | Annexon, Inc. | 14 | 2020-01-29 | 2021-08-11 |
| Small Volume Plasma Exchange (SVPE) for Guillain-Barré Syndrome (GBS) Patients Small Volume Plasma Exchange - Guillain-Barré Syndrome | Phase 2 | Completed | International Centre for Diarrhoeal Disease Research, Bangladesh | 20 | 2016-01-01 | 2017-07-27 |
| Phase III Clinical Trial of NPB-01 in Patients With Guillain-Barré Syndrome NPB-01 - Guillain-Barré Syndrome | Phase 3 | Completed | Nihon Pharmaceutical Co., Ltd | 22 | 2014-10-01 | 2017-04-12 |
| Efficacy and Safety Study of GB-0998 for Guillain-Barré Syndrome GB-0998 - Guillain-Barré Syndrome | Phase 3 | Completed | Japan Blood Products Organization | 21 | 2014-08-01 | 2016-02-04 |
| International Guillain-Barré Syndrome Outcome Study Guillain-Barré Syndrome, Miller Fisher Syndrome | Completed | Erasmus Medical Center | 2000 | 2012-05-01 | 2024-12-12 |
Guillain-Barre Syndrome (10) · Neuromuscular Diseases (2) · Amyotrophic Lateral Sclerosis (1) · Autoimmune Diseases (1) · Friedreich Ataxia (1) · Glycogen Storage Disease Type II (1) · Hereditary Sensory and Motor Neuropathy (1) · Immune System Diseases (1) · Infections (1) · Lambert-Eaton Myasthenic Syndrome (1) · Miller Fisher Syndrome (1) · Muscular Atrophy, Spinal (1) · Muscular Dystrophy, Facioscapulohumeral (1) · Myasthenia Gravis (1) · Myositis, Inclusion Body (1)
Autoimmune Diseases of the Nervous System (10) · Chronic Disease (10) · Demyelinating Diseases (10) · Disease Attributes (10) · Nervous System Diseases (10) · Pathologic Processes (10) · Pathological Conditions, Signs and Symptoms (10) · Peripheral Nervous System Diseases (10) · Polyradiculoneuropathy (10) · Post-Infectious Disorders (10) · Autoimmune Diseases (9) · Immune System Diseases (9) · Polyneuropathies (9) · Neuromuscular Diseases (8) · Brain Diseases (2)
Immunoglobulins, Intravenous (2) · gamma-Globulins (1)
Annexon, Inc. (1) · Beijing Tiantan Hospital (1) · Cellenkos, Inc. (1) · Centro de Reabilitacao do Norte (1) · Erasmus Medical Center (1) · Hoffmann-La Roche (1) · International Centre for Diarrhoeal Disease Research, Bangladesh (1) · Japan Blood Products Organization (1) · LMU Klinikum (1) · Nihon Pharmaceutical Co., Ltd (1)
Bangladesh (3) · Japan (3) · Denmark (2) · Germany (2) · Argentina (1) · Australia (1) · Belgium (1) · Canada (1) · China (1) · France (1) · Greece (1) · Italy (1) · Malaysia (1) · Netherlands (1) · Portugal (1)
Alda S Marques, PhD (1) · Bart Jacobs, Dr. (1) · Kyoichi Nomura (1) · Tara Sadeghi (1) · Zhahirul Islam, PhD (1)
PMID 16267188, PMID 16849828, PMID 16900450, PMID 22003934, PMID 28168524, PMID 28406555, PMID 28975040, PMID 30121613, PMID 34937789